911593

NanoFabTx^™ microfluidic - nano

device kit for synthesis of 100-200 nm nanoparticles and liposomes

• Sinonimo/i: Liposomes, Microfluidic kit, NanoFabTx^™ device kit, Nanoformulation, Nanoparticle
• Codice UNSPSC: 12162002
• Codice UNSPSC: 41121811

Proprietà

• Descrizione: Microfludic device kit for synthesizing nanparticles; ; Kit components : ;
  • Microfluidic chip x 1
  • Tubings and accessories
• Livello qualitativo: 100
• applicazioni: advanced drug delivery

Descrizione

Descrizione generale

NanoFabTx^™ Microfluidic - nano device kit is a set of plug-and-play, easy-to-use microfluidic components that are compatible with Dolomite microfluidic systems and standard syringe pumps (not included). The device kit can be combined with our special nanoformulation kits (please visit www.sigmaaldrich.com/nanofabtx) to form nanoparticles or liposomes 100 to 200 nm in size. The device kit includes a comprehensive protocol, pre-assembled microfluidic chip manifold, tubing, and required accessories.

Applicazioni

NanoFabTx^™ Microfluidic - nano device kit is designed to work with NanoFabTx^™ - nano reagent kits (including 909637, 918075, and 907766) to synthesize drug-encapsulating liposome nanoparticles (LNP) and drug-encapsulating polymeric nanoparticles for targeted drug delivery research. Our device kit simplifies LNP formulation and polymeric nanoformulation by leveraging microfluidic technologies to achieve narrow size dispersity and high batch-to-batch consistency. The microfluidic chip manifold is chemically robust and compatible with a variety of solvents and therapeutics relevant in nanomedicine. The microfluidic chip geometries and controllable flow enable the user to achieve targetable particle diameters with homogenous shape and structure from 100 to 200 nm in size. By enabling users to easily fine-tune the synthetic parameters, our microfluidic-based tool allows scalable synthesis of drug-encapsulating nanocarriers for researchers in the field of precision medicine, drug discovery, and nanoparticle cancer treatment.

Caratteristiche e vantaggi

• Step-by-step microfluidic-based protocols developed and tested by our formulation scientists
• Optimization of drug encapsulation and loading efficiency in nanoparticles and liposomes
• Selection of optimal nanoparticle and liposome size of any size between 100-200 nm
• Small reaction volumes to reduce waste of expensive reagents and therapeutics

Note legali

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC